Incident dementia risk among patients with type 2 diabetes receiving metformin versus alternative oral glucose-lowering therapy: an observational cohort study using UK primary healthcare records.
William DoranLouis TunnicliffeRutendo MuzambiChristopher T RentschKrishnan BhaskaranLiam SmeethCarol BrayneDylan M WilliamsNish ChaturvediSophie V EastwoodSusanna J DunachieRohini MathurCharlotte Warren-GashPublished in: BMJ open diabetes research & care (2024)
Metformin use was associated with lower risks of incident dementia and MCI compared with alternative GLT among UK adults with diabetes. While our findings are consistent with a neuroprotective effect of metformin against dementia, further research is needed to reduce risks of confounding by indication and assess causality.
Keyphrases
- mild cognitive impairment
- cardiovascular disease
- healthcare
- cognitive impairment
- type diabetes
- human health
- cross sectional
- risk assessment
- emergency department
- stem cells
- glycemic control
- cerebral ischemia
- bone marrow
- insulin resistance
- mesenchymal stem cells
- health information
- electronic health record
- skeletal muscle